Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report

Enfortumab vedotin is a novel breakthrough therapy that received accelerated US Food and Drug Administration approval in 2019 for the treatment of metastatic urothelial carcinoma in patients who have failed other lines of treatment. The characteristics of its adverse effects are not well understood....

Descripción completa

Detalles Bibliográficos
Autores principales: Atemnkeng, Francis, Aguilar, Fatima, Gupta, Sanjeev, Chugh, Savneek, Klein, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651765/
https://www.ncbi.nlm.nih.gov/pubmed/38028029
http://dx.doi.org/10.1016/j.xkme.2023.100737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651765/
https://www.ncbi.nlm.nih.gov/pubmed/38028029
http://dx.doi.org/10.1016/j.xkme.2023.100737

Ejemplares similares